CRYOPORT, INC. Available-for-sale Securities, Amortized Cost Basis
CRYOPORT, INC. (CYRX) had Available-for-sale Securities, Amortized Cost Basis of $9.93 million as of 2019-06-30, per its 10-Q filed 2019-08-09.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2019-08-09
- 2019-06-30: Available-for-sale Securities, Amortized Cost Basis $9.93M.
- 2019-03-31: Available-for-sale Securities, Amortized Cost Basis $11.40M.
- 2018-12-31: Available-for-sale Securities, Amortized Cost Basis $7.90M.
- 2018-09-30: Available-for-sale Securities, Amortized Cost Basis $9.92M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2019-06-30 | $9.93M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $11.40M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $7.90M 10-Q · filed 2019-08-09 |
| 2018-09-30 | $9.92M 10-Q · filed 2018-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |